Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Alex Z. Wang, Amir H. Lebastchi, Luke P. O’Connor, Michael Ahdoot, Sherif Mehralivand, Nitin Yerram, Samir S. Taneja, Arvin K. George, Rafael Sanchez-Salas, John F. Ward, Pilar Laguna, Jean de la Rosette, Peter A. Pinto

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical “middle ground” in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.

    Original languageEnglish (US)
    Pages (from-to)729-739
    Number of pages11
    JournalWorld Journal of Urology
    Volume39
    Issue number3
    DOIs
    StatePublished - Mar 2021

    Keywords

    • Focal therapy
    • MRI
    • prostate cancer

    ASJC Scopus subject areas

    • Urology

    Fingerprint

    Dive into the research topics of 'Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials'. Together they form a unique fingerprint.

    Cite this